
Haleon plc: Director/PDMR Shareholding
13 January 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
a)
|
Name
|
Adrian Morris
|
2
|
Reason for the notification
|
a)
|
Position/status
|
General Counsel - PDMR
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Haleon plc
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary Shares of £0.01 each
|
|
|
Identification code
|
GB00BMX86B70
|
|
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
£3.7738
|
33
|
|
|
|
£Nil
|
33 (Matching Shares)
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
- Aggregated volume
|
66
|
|
|
- Price
|
|
|
|
e)
|
Date of the transaction
|
10 January 2025
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
a)
|
Name
|
Tamara Rogers
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Marketing Officer - PDMR
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Haleon plc
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary Shares of £0.01 each
|
|
|
Identification code
|
GB00BMX86B70
|
|
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
£3.7738
|
33
|
|
|
|
£Nil
|
33 (Matching Shares)
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
- Aggregated volume
|
66
|
|
|
- Price
|
|
|
|
e)
|
Date of the transaction
|
10 January 2025
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.